Protagonist Therapeutics share price logo

Protagonist Therapeutics

NASDAQ: PTGX

Mid Cap

$144.98

+1.98

(+1.38%)

as on

Protagonist Therapeutics Stock Performance

as on September 22, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $141.09
    $145.36
    downward going graph

    2.68%

    Downside

    0.26%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $61.95
    $160.81
    downward going graph

    57.27%

    Downside

    10.92%

    Upside

    downward going graph

Protagonist Therapeutics share price movements today

Previous Close
$143.00
Open
$142.78
Volume
378.0K
Market Cap
$9.3B
Day's Low - High
$141.09 - $145.36
52 Week Low - High
$61.95 - $160.81

Protagonist Therapeutics Historical Returns

1 Month Return
-6.05 %
3 Month Return
+ 26.04 %
1 Year Return
+ 124.74 %
3 Year Return
+ 747.34 %
5 Year Return
+ 837.17 %

Protagonist Therapeutics Stock Fundamentals & Key Indicators

Check Protagonist Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$9.3B

EPS (TTM)

1.2181

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

3.51%

PE Ratio (TTM)

117.4

Industry PE ratio

-13.56

PEG Ratio

-0.1394193490370275

EBITDA

85.5M

Revenue (TTM)

282.0M

Profit Margin

99.86%

Return On Equity TTM

12.03%

Protagonist Therapeutics Stock Valuation

Track how Protagonist Therapeutics P/E has moved over time to understand its valuation trends.

Protagonist Therapeutics in the last 5 years

  • Overview

  • Trends

Lowest (-42.60x)

December 31, 2025

Today (-42.60x)

December 31, 2025

Industry (-13.56x)

December 31, 2025

Highest (8.64x)

December 31, 2024

LowHigh

Today’s Price to Earnings Ratio: -42.60x

Protagonist Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Protagonist Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$9.3B837.17%117.499.86%0.00%
Neutral$61.5B-60.76%-19.3-12.57%0.00%
StrongBuy$128.8B177.16%29.3586.04%0.00%
Buy$80.8B23.35%18.4884.86%0.47%

Stock Returns calculator for Protagonist Therapeutics Stock including INR - Dollar returns

The Protagonist Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Protagonist Therapeutics investment value today

Current value as on today

₹2,43,834

Returns

₹1,43,834

(+143.83%)

Returns from Protagonist Therapeutics Stock

₹1,24,740 (+124.74%)

Dollar Impact

₹19,093 (+19.09%)

Analyst Recommendation on Protagonist Therapeutics Stock

Based on 12 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 12 analysts, 100% of analysts recommend a 'BUY' rating for Protagonist Therapeutics. Average target price of $174.69

Protagonist Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Protagonist Therapeutics.

What analysts predicted

17.01%UPSIDE

Target Price

$174.69

Current Price

$144.98

Analyzed by

12 Analysts

Target

$174.69

Protagonist Therapeutics target price $174.69, a slight upside of 17.01% compared to current price of $144.98. According to 12 analysts rating.

Indian Investors' Interest in Protagonist Therapeutics Stock

Search interest for Protagonist Therapeutics Stock has decreased by -42% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-42% versus previous 30 day period

Protagonist Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
254
4
4
170
28
5
4
7
56
213
Gross Profit
254
4
4
170
28
5
4
7
55
213
Operating Income
206
-38
-41
126
-19
-42
-46
-50
-3
158
EBITDA
210
-29
-32
134
-11
-34
-38
-43
2
165
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
1
0
0
0
0
0
0
0
-
Income Before Tax
210
-31
-33
133
-11
-34
-39
-43
2
165
Income Tax Expense
3
0
0
1
-
0
-
0
-1
2
Net Income
207
-30
-33
131
-11
-34
-39
-44
3
162
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
99.28%
100.00%

Protagonist Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
20
30
0
28
27
26
60
434
46
Gross Profit
20
30
0
28
27
26
60
434
44
Operating Income
-37
-42
-80
-64
-125
-131
-93
252
-158
EBITDA
-36
-39
-77
-63
-122
-124
-75
280
-128
Interest Expense
-
-
0
0
-
-
-
-
-
Depreciation
0
0
0
0
2
3
3
0
1
Income Before Tax
-36
-39
-77
-64
-125
-127
-78
279
-129
Income Tax Expense
-
0
0
1
-
-
-
4
0
Net Income
-36
-38
-77
-66
-125
-127
-78
275
-130
Net Profit Margin
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
100.00%
97.34%

Protagonist Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
207
-30
-33
131
-11
-34
-39
85
3
162
Operating Cash Flow
-27
268
-27
-29
125
-28
-1
-36
-48
219
Investing Cash Flow
6
-88
-208
-8
-94
54
-58
48
90
-2
Financing Cash Flow
7
2
12
4
11
2
5
2
23
9
Change in Cash
-14
183
-224
-33
42
28
-54
14
65
226

Protagonist Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-36
-38
-77
-66
-125
-127
-78
275
-
Operating Cash Flow
3
-49
-41
-72
-107
-108
-70
184
57
Investing Cash Flow
15
2
-53
-90
-15
91
-39
-299
-49
Financing Cash Flow
65
24
46
247
129
18
170
25
22
Change in Cash
85
-23
-49
84
6
2
60
-89
31

Mutual Funds that own Protagonist Therapeutics Stock

Check out the Mutual Funds with significant holdings in Protagonist Therapeutics.

Funds
Holdings
Shares Held
VANGUARD INDEX FUNDS
7.707968%
4987694
VANGUARD SPECIALIZED FUNDS
2.133335%
1380445
T. ROWE PRICE HEALTH SCIENCES FUND, INC.
1.764934%
1142059
JANUS INVESTMENT FUND
1.536664%
994349
Fidelity Salem Street Trust
1.211806%
784139

Global Institutional Holdings in Protagonist Therapeutics

Funds
Holdings
iShares
11.52%
Andrew J.M. Spokes
9.81%
Vanguard
9.3%
SPDR
3.28%
Michael Rockefeller
2.19%

Protagonist Therapeutics News & Key Events

  • img

    Today's Timeline - 31 August

    Mon, 11:32 PM

    -

    Protagonist Therapeutics receives FDA approval for rusfertide, marking its second approved medicine this year, with significant financial implications.

Insights on Protagonist Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, PTGX has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, PTGX stock has moved up by 124.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 551.1% return, outperforming this stock by 426.4%

About Protagonist Therapeutics

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
OrganisationProtagonist Therapeutics
Headquarters7707 Gateway Boulevard, Newark, CA, 94560, US
IndustryBiotechnology
CEODinesh V. Patel
E-voting on sharesClick here to vote

Key Management of Protagonist Therapeutics

Name

Title

Dr. Ashok Bhandari Ph.D.

EVP & Chief Discovery Officer

Mr. Carter J. King

Executive Vice President of Business Development

Ms. Abha Bommireddi

Executive VP & Chief of Staff

Dr. Dinesh V. Patel Ph.D.

CEO, President, Secretary & Director

Mr. Asif Ali

Executive VP & CFO

Mr. Venkat Thalladi Ph.D.

EVP & Chief Technical Officer

Dr. Newman Yeilding M.D.

Executive VP, Chief Scientific Officer

Dr. Arturo M. Molina FACP, M.D., M.S.

Chief Medical Officer

Mr. Matthew M. Gosling J.D.

Executive VP and Chief Legal & Business Officer

Ms. Carena Spivey

Executive VP & Chief Human Resources Officer

FAQs

What is Protagonist Therapeutics share price today?

Protagonist Therapeutics share price today is $144.98 as on at the close of the market. Protagonist Therapeutics share today touched a day high of $145.36 and a low of $141.09.

What is the 52 week high and 52 week low for Protagonist Therapeutics share?

Protagonist Therapeutics share touched a 52 week high of $160.81 on and a 52 week low of $61.95 on . Protagonist Therapeutics stock price today i.e. is closed at $144.98,which is 9.84% down from its 52 week high and 134.03% up from its 52 week low.

What is Protagonist Therapeutics's market capitalisation today?

Protagonist Therapeutics market capitalisation is $0.01T as on .

How to invest in Protagonist Therapeutics Stock (PTGX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Protagonist Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Protagonist Therapeutics Shares that will get you 0.0103 shares as per Protagonist Therapeutics share price of $144.98 per share as on September 22, 2026 at 8:46 am IST.

What is the minimum amount required to buy Protagonist Therapeutics Stock (PTGX) from India?

Indian investors can start investing in Protagonist Therapeutics (PTGX) shares with as little as ₹95.805 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹958.05 in Protagonist Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Protagonist Therapeutics share’s latest price of $144.98 as on September 22, 2026 at 8:46 am IST, you will get 0.0690 shares of Protagonist Therapeutics. Learn more about fractional shares .

What are the returns that Protagonist Therapeutics has given to Indian investors in the last 5 years?

Protagonist Therapeutics stock has given 837.17% share price returns and 30.09% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?